Last reviewed · How we verify
NCT06888622
BLAZE-Limiting Approach in NMOSD
trial testing Eculizumab administration in Neuromyelitis Optica Spectrum Disorders (NMOSD) in 9 participants. Completed in 3 March 2025.
1 March 2025
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 1 October 2023 |
| Primary completion | 1 March 2025 |
| Estimated completion | 3 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Eculizumab administration — full drug profile →
Conditions studied
- Neuromyelitis Optica Spectrum Disorders (NMOSD) — all drugs for Neuromyelitis Optica Spectrum Disorders (NMOSD) →
Sponsor
Huashan Hospital
Who can join
18 and older, any sex, with Neuromyelitis Optica Spectrum Disorders (NMOSD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06888622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eculizumab administration
Trials testing the same drug.
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Other recruiting trials for Neuromyelitis Optica Spectrum Disorders (NMOSD)
Currently open trials in the same condition.
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06888622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing